Table 3.
Effect of dopamine depletion of D2 receptor availability in controls and first-episode and chronic patients with schizophrenia
| Subjects | n | Age, years | Gender (M/F) | [123I]IBZM BP
|
α-MPT effect on [123I]IBZM BP, % | α-MPT in plasma, μg/ml | |
|---|---|---|---|---|---|---|---|
| Baseline | Post-α-MPT | ||||||
| Controls | 18 | 31 ± 8 | 7/11 | 0.72 ± 0.09 | 0.79 ± 0.10 | 9 ± 7 | 19 ± 6 |
| Patients with schizophrenia | |||||||
| Neuroleptic-naive first-episode | 8 | 30 ± 7 | 5/3 | 0.72 ± 0.07 | 0.84 ± 0.06 | 17 ± 6** | 21 ± 8 |
| Neuroleptic-free chronic | 10 | 32 ± 9 | 2/8 | 0.78 ± 0.12 | 0.93 ± 0.15* | 20 ± 15** | 21 ± 5 |
*, Significantly different from controls, unpaired t test, P < 0.05; **, significantly different compared with controls, repeated-measure ANOVA, group × effect interaction, P < 0.01.